Stay updated on Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial page.

Latest updates to the Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe ClinicalTrials.gov record for this mesothelioma trial is displayed with its study design, eligibility criteria, outcome measures, participating locations, and study documents.SummaryDifference89%

- Check16 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA banner was added announcing NIH website updates and a transition from using “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference1%

- Check30 days agoChange DetectedThe site footer revision label changed from v3.7.1 to v3.7.2; the study record remains unavailable on the error page.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site footer revision advances from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

- Check58 days agoChange Detected403 Forbidden page now appears, replacing the normal study content and navigation. This blocks access to the trial details and locations.SummaryDifference21%

Stay in the know with updates to Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial page.